此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Genicular Nerve Radiofrequency Ablation Versus Hyaluronic Acid Injection for Knee Osteoarthritis Pain (RF-PROSPECTIU)

2026年11月11日 更新者:Laura Pallarès Valls、Hospital Universitari Joan XXIII de Tarragona.

A Prospective Comparative Study of Conventional Conservative Treatment Versus Genicular Radiofrequency Ablation in Non-Surgical Knee Osteoarthritis: A Randomized Controlled Trial of Thermal Radiofrequency of the Genicular Nerves Versus Intra-Articular Hyaluronic Acid

The goal of this clinical trial is to learn if thermal radiofrequency ablation of the genicular nerves (the nerves that carry pain signals from the knee) works better than a single injection of hyaluronic acid into the knee to relieve pain in adults with knee osteoarthritis who have not improved with conservative treatment. The study also includes patients with severe knee osteoarthritis who are not candidates for knee replacement surgery.

The main questions it aims to answer are:

  • Does genicular nerve radiofrequency reduce knee pain during movement more than hyaluronic acid over 12 months?
  • Does it improve knee function and quality of life, and does its effect last longer?

Researchers will compare radiofrequency ablation with hyaluronic acid injection to see which treatment gives greater and longer-lasting pain relief.

Participants will:

  • Be randomly assigned to one of the two treatments.
  • If assigned to radiofrequency, first receive a diagnostic nerve block with local anesthetic. Only those whose pain decreases by at least 50% will then receive radiofrequency ablation, in a single ultrasound-guided session.
  • If assigned to hyaluronic acid, receive a single injection of hyaluronic acid into the knee.
  • Attend follow-up visits at 1, 3, 6 and 12 months, where they will rate their pain and answer questionnaires about knee function, overall status and quality of life.

研究概览

详细说明

Knee osteoarthritis is a leading cause of chronic pain and disability. Conventional conservative treatments, such as non-steroidal anti-inflammatory drugs and intra-articular hyaluronic acid, provide partial and time-limited relief. Thermal radiofrequency ablation of the genicular nerves is a minimally invasive technique that interrupts pain transmission from the knee joint. Most published studies have short follow-up (3-6 months), and evidence is scarce in patients with advanced osteoarthritis (Kellgren-Lawrence grade IV) who are not candidates for total knee arthroplasty because of severe comorbidity, morbid obesity or a documented multidisciplinary decision.

Design: single-center, randomized, parallel-group (1:1) controlled trial conducted at Hospital Universitari Joan XXIII de Tarragona (Spain). Patients and clinicians are not blinded; the outcome assessor and the statistician are blinded to treatment allocation.

Randomization: computer-generated sequence (sealedenvelope.com) with variable block sizes, stratified by Kellgren-Lawrence grade (II-III vs IV) and body mass index (<40 vs >=40 kg/m2).

Interventions: in the radiofrequency group, an ultrasound-guided diagnostic block of the superomedial, superolateral and inferomedial genicular nerves (1 ml of 1% lidocaine per nerve) is performed first. Patients with at least 50% pain reduction within 4 hours undergo ultrasound-guided thermal radiofrequency ablation of the same nerves (80 C for 90 seconds per nerve). Patients with a negative block do not receive radiofrequency, are withdrawn from the study and are reported in the CONSORT flow diagram. In the hyaluronic acid group, patients receive a single 6 ml intra-articular injection of high molecular weight hyaluronic acid (hylan G-F 20 or similar).

Sample size: 25 patients per group are required to detect a minimal clinically important difference of 2 points in the visual analogue scale (standard deviation 2.5, power 80%, two-sided alpha 0.05). Allowing for 20% losses over 12 months, 35 patients per group (70 in total) will be included.

A pre-specified subgroup analysis will compare treatment response in Kellgren-Lawrence grade II-III versus grade IV patients, and according to comorbidity (Charlson Comorbidity Index) and body mass index. Health-related quality of life data will be collected for a potential cost-effectiveness analysis.

研究类型

介入性

注册 (估计的)

70

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Tarragona
      • Tarragona、Tarragona、西班牙、43005
        • Hospital Universitari Joan XXIII de Tarragona
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Adults (18 years or older) with symptomatic knee osteoarthritis of more than 6 months' duration.
  • Pain during movement >4 on a 0-10 visual analogue scale.
  • Failure of conservative treatment: pain during movement >4 despite at least 3 months of NSAIDs and/or rehabilitation (physical therapy), documented in the medical record. Patients with a documented contraindication to NSAIDs may be included if they have undergone rehabilitation.
  • Radiographic Kellgren-Lawrence grade II or III, or
  • Kellgren-Lawrence grade IV in patients who are not candidates for total knee arthroplasty because of at least one of the following: body mass index >39.9 kg/m2; Charlson Comorbidity Index >=5 (original, not age-adjusted); or a documented multidisciplinary decision of the Orthopaedic Surgery Department.
  • Signed informed consent.

Exclusion Criteria:

  • Acute or chronic knee joint infection.
  • Intra-articular hyaluronic acid or corticosteroid injection in the previous 6 months.
  • Coagulopathy or anticoagulant treatment that does not allow a safe therapeutic window for the procedure.
  • Major lower limb surgery in the previous 6 months that may affect function or pain of the index knee (including contralateral total or partial knee arthroplasty, hip arthroplasty, or tibial or femoral osteotomy).
  • Cardiac pacemaker or metallic implant (contraindication for radiofrequency).
  • Known allergy to hyaluronic acid.
  • Severe dementia.
  • Institutionalized patients.
  • Decompensated systemic disease.
  • Active neurological or inflammatory rheumatological disease.
  • Terminal oncological disease.
  • Inability to understand the study questionnaires.
  • Radiofrequency arm only: negative diagnostic genicular nerve block (<50% pain reduction within 4 hours).

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:单身的

武器和干预

参与者组/臂
干预/治疗
实验性的:Genicular Nerve Radiofrequency Ablation

Ultrasound-guided diagnostic block of the superomedial, superolateral and inferomedial genicular nerves with 1 ml of 1% lidocaine per nerve. Participants with at least 50% pain reduction within 4 hours undergo ultrasound-guided thermal radiofrequency ablation of the same three nerves (80 C for 90 seconds per nerve) in a single session. Participants with a negative block do not receive radiofrequency and are withdrawn from the study.

Ultrasound-guided thermal radiofrequency ablation (80 C, 90 seconds per nerve) of the superomedial, superolateral and inferomedial genicular nerves, performed only after a positive diagnostic block (>=50% pain reduction within 4 hours after 1 ml of 1% lidocaine per nerve).

有源比较器:Intra-articular Hyaluronic Acid

Single intra-articular injection of 6 ml of high molecular weight hyaluronic acid (hylan G-F 20, Synvisc-One, or similar) into the index knee.

Single 6 ml intra-articular injection of high molecular weight hyaluronic acid into the index knee.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Change in Knee Pain During Movement (Visual Analogue Scale)
大体时间:Baseline, 1, 3, 6 and 12 months after the intervention

Pain during movement (walking or climbing stairs) in the index knee, measured on a 100 mm visual analogue scale and recorded in cm with one decimal (0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain.

Baseline, 1, 3, 6 and 12 months after the intervention

次要结果测量

结果测量
措施说明
大体时间
Change in Knee Pain at Rest (Visual Analogue Scale)
大体时间:Baseline, 1, 3, 6 and 12 months after the intervention

Pain at rest in the index knee, measured on a 100 mm visual analogue scale and recorded in cm with one decimal (0 = no pain, 10 = worst imaginable pain). Higher scores indicate worse pain.

Baseline, 1, 3, 6 and 12 months after the intervention
Change in Knee Function (WOMAC)
大体时间:Baseline, 1, 3, 6 and 12 months after the intervention

Western Ontario and McMaster Universities Osteoarthritis Index (Likert 3.1). Total score 0-96 and subscales for pain (0-20), stiffness (0-8) and physical function (0-68). Higher scores indicate worse symptoms and function.

Baseline, 1, 3, 6 and 12 months after the intervention
Proportion of Participants Achieving the Minimal Clinically Important Difference in Pain
大体时间:1, 3, 6 and 12 months after the intervention

Percentage of participants with a reduction of at least 2 points from baseline in pain during movement (visual analogue scale, 0-10).

1, 3, 6 and 12 months after the intervention
Analgesic Consumption
大体时间:Baseline, 1, 3, 6 and 12 months after the intervention

Number of days with analgesic use in the previous 4 weeks (0-28) and most potent analgesic used (none, paracetamol, NSAID, weak opioid, strong opioid).

Baseline, 1, 3, 6 and 12 months after the intervention
Number of Participants With Adverse Events
大体时间:Up to 12 months after the intervention

Adverse events related to the diagnostic block, radiofrequency ablation or hyaluronic acid injection, systematically recorded at each visit.

Up to 12 months after the intervention
Retreatment or Rescue Treatment
大体时间:Up to 12 months after the intervention

Proportion of participants requiring retreatment, rescue treatment (including corticosteroid injection) or indication of total knee arthroplasty, and time to first retreatment or rescue treatment.

Up to 12 months after the intervention
Health-Related Quality of Life (EQ-5D-5L)
大体时间:Baseline, 6 and 12 months after the intervention

EQ-5D-5L descriptive system (5 dimensions, 5 levels; utility index calculated with the Spanish value set, where 1 = full health and higher values indicate better health) and EQ-VAS (0-100, higher scores indicate better health).

Baseline, 6 and 12 months after the intervention
Rate of Negative Diagnostic Genicular Nerve Blocks
大体时间:4 hours after the diagnostic block

Percentage of participants allocated to the radiofrequency arm with less than 50% pain reduction within 4 hours after the diagnostic block, who therefore do not receive radiofrequency ablation.

4 hours after the diagnostic block
Patient Global Assessment
大体时间:Baseline, 1, 3, 6 and 12 months after the intervention

Patient global assessment of the impact of knee osteoarthritis, measured on a 100 mm visual analogue scale (0 = very well, 100 = very poor). Higher scores indicate worse status.

Baseline, 1, 3, 6 and 12 months after the intervention
Patient Global Impression of Change (PGIC)
大体时间:1, 3, 6 and 12 months after the intervention

Single 7-point item from "very much better" to "very much worse" compared with before the study treatment. Responders are participants reporting "much better" or "very much better".

1, 3, 6 and 12 months after the intervention
Proportion of OMERACT-OARSI Responders
大体时间:1, 3, 6 and 12 months after the intervention

Responder according to OMERACT-OARSI criteria, based on pain during movement, WOMAC physical function and patient global assessment, each expressed on a 0-100 scale: improvement in pain or function >=50% and >=20 points, or improvement >=20% and >=10 points in at least two of the three domains.

1, 3, 6 and 12 months after the intervention

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Laura Pallarès Valls, MD、Hospital Universitari Joan XXIII de Tarragona.

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年11月1日

初级完成 (估计的)

2028年5月1日

研究完成 (估计的)

2028年5月1日

研究注册日期

首次提交

2026年10月21日

首先提交符合 QC 标准的

2026年10月21日

首次发布 (实际的)

2026年10月28日

研究记录更新

最后更新发布 (实际的)

2026年11月13日

上次提交的符合 QC 标准的更新

2026年11月11日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

其他研究编号

  • Ceim-116/2026
  • 116/2026 (其他标识符:CEIm IISPV (Research Ethics Committee) reference number)

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

IPD 计划说明

Individual participant data will not be shared publicly, as participant consent for data sharing was not obtained and data are protected under the EU General Data Protection Regulation (GDPR). Data will be pseudonymized using participant codes and entered into REDCap, where the statistical analysis will be performed. Aggregated results will be published in peer-reviewed journals.

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅